

**Cancer Surveillance Research**

See commentary, p. 2428

**Five-Year and Lifetime Risk of Breast Cancer among U.S. Subpopulations: Implications for Magnetic Resonance Imaging Screening**Barry I. Graubard<sup>1</sup>, Andrew N. Freedman<sup>2</sup>, and Mitchell H. Gail<sup>1</sup>**Abstract**

**Background:** Guidelines from the American Cancer Society recommend annual breast magnetic resonance imaging (MRI) screening for women with a projected lifetime risk of  $\geq 20\%$  based on risk models that use family history. Because MRI screening is costly and has limited specificity, estimates of the numbers of U.S. women with  $\geq 20\%$  breast cancer risk would be useful.

**Methods:** We used data from the 2000 and 2005 National Health Interview Survey and the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool (i.e., Gail model 2 with a revision for African Americans) to calculate estimates of U.S. women by age and race/ethnicity categories with a lifetime absolute breast cancer risk of  $\geq 20\%$ . Distributions of 5-year and lifetime absolute risk of breast cancer were compared across demographic groups.

**Results:** We estimated that 1.09% (95% confidence interval, 0.95-1.24%) of women age 30 to 84 years have a lifetime absolute breast cancer risk of  $\geq 20\%$ , which translates to 880,063 U.S. women eligible for MRI screening. The 5-year risks are highest for white non-Hispanics and lowest for Hispanics. The lifetime risks decrease with age and are generally highest for white non-Hispanics, lower for African American non-Hispanic, and lowest for Hispanics.

**Conclusion:** We provide national estimates of the number of U.S. women who would be eligible for MRI breast screening and distributions of 5-year and lifetime risks of breast cancer using the NCI Breast Cancer Risk Assessment Tool.

**Impact:** These estimates inform the potential resources and public health demand for MRI screening and chemopreventive interventions that might be required for U.S. women. *Cancer Epidemiol Biomarkers Prev*; 19(10); 2430-6. ©2010 AACR.

**Introduction**

In response to new data on the sensitivity and specificity of magnetic resonance imaging (MRI) to screen and diagnose high-risk women for breast cancer, the American Cancer Society (ACS) updated guidelines for the use of MRI as an adjunct to mammography in breast cancer screening (1). These guidelines recommend annual breast MRI for women who carry, or have a first-degree relative who carries, a mutation in the *BRCA1* or *BRCA2* gene, women in families with rare familial syndromes such as the Li and Fraumeni syndrome, or women who received therapeutic chest radiation at ages 10 to 30 years,

and women with a projected lifetime risk of  $\geq 20\%$  based on "risk models that are largely dependent on family history." A number of models are available for predicting lifetime risk (2). One such model is the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool, sometimes called the Gail model 2, which is a widely used tool to identify women at high risk of breast cancer for multiple purposes (2-4). This model includes age at menarche, age at first birth, and personal history of benign breast biopsies and of atypical hyperplasia, in addition to family history of breast cancer.

Because MRI breast cancer screening is costly and has been shown to have limited specificity (5, 6), it would be useful to provide health researchers and policy analysts with nationally representative estimates of the numbers of U.S. women with a breast cancer risk estimate that would meet the criterion of the ACS of  $\geq 20\%$  lifetime risk for breast cancer screening with MRI. In this article we present the numbers and percentages of women who meet this criterion and present estimated distributions of 5-year and lifetime absolute risk of breast cancer using smaller cutoffs such as the 1.67% 5-year absolute risk used to determine eligibility for tamoxifen in the Breast

**Authors' Affiliations:** Divisions of <sup>1</sup>Cancer Epidemiology and Genetics, and <sup>2</sup>Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland

**Corresponding Author:** Barry I. Graubard, Biostatistics Branch, Division of Cancer Epidemiology and Genetics, Executive Plaza South Room 8024, 6120 Executive Boulevard, Bethesda, MD 20892. Phone: 301-496-7455; Fax: 301-402-0081. E-mail: graubarb@mail.nih.gov

doi: 10.1158/1055-9965.EPI-10-0324

©2010 American Association for Cancer Research.

Cancer Prevention Trial (7). Little work has been done to compare these distributions of absolute risk across race/ethnic groups and age groups. These population estimates of the numbers of women who are at various levels of elevated risk of breast cancer provide public health researchers with determinants of future demand for chemopreventive agents and for breast cancer screening. We combine data collected in National Health Interview Survey (NHIS) conducted in 2000 and 2005 to calculate the percentage and number of U.S. women with a lifetime absolute risk estimate of breast cancer based on the NCI Breast Cancer Risk Assessment Tool separately for white, African American, and Hispanic women in various age categories.

## Materials and Methods

The NHIS is a nationally representative annual household survey that collects health-related data using stratified multistage cluster probability sampling of the noninstitutionalized civilian U.S. population (8, 9). The survey is conducted by the National Center for Health Statistics, using interviewers from the U.S. Census Bureau, and collects data for all family members from a sampled household. The survey provides national data on basic demographics, incidence of illness and accidental injuries, prevalence of chronic conditions and impairments, and usage of health services. The data in these analyses come from two surveys conducted during the years 2000 and 2005 (8, 9). During those years the NHIS contained a Cancer Control Survey Module (CCM), which was designed and funded by the National Cancer Institute and the Centers for Disease Control and Prevention. This module collected additional data on risk factor and screening practices related to cancer from one randomly sampled adult 18 years and older from each sampled family in a sampled household. For the 2000 NHIS, 39,264 families were interviewed, from which 39,201 eligible adults were sampled for the CCM with data collected from 32,374. For the 2005 NHIS, 39,284 families were interviewed, from which 39,227 eligible adults were sampled for the CCM, with data collected from 31,321. The overall response rates for 2000 and 2005 CCM were 72.1% and 69.0%, respectively.

## Statistical methods

The 2000 and 2005 NHIS CCM included questions for risk factors that were included in the original model of Gail et al. (10, 11). These risk factors were age, age at first live birth, age at menarche, number of first-degree relatives with breast cancer, and number of breast biopsies. About 13% of women had missing values for one or more of these risk factors. In these cases, the missing risk factors were coded to the lowest category of risk. This model, which has been validated in multiple settings, calculates women's absolute risk of developing breast cancer for different time intervals (e.g., 5 years, 10 years, and lifetime). The NCI Breast Cancer Risk Assessment Tool

uses the modified version of this model (Gail model 2) given by Costantino et al. (3) and Anderson et al. (12) to calculate risks for white non-Hispanic women. For non-Hispanic African Americans, the NCI Breast Cancer Risk Assessment Tool uses the version of Gail et al. (13) that was specifically modified to produce risk estimates for this racial group. The NCI Breast Cancer Risk Assessment Tool makes projections for Hispanic women and for other racial and ethnic subgroups by combining relative and attributable risks from data from white women with breast cancer incidence and mortality rates specific for the ethnic or racial subgroup from NCI's Surveillance, Epidemiology and End Results Program. Because of small sample sizes we do not provide separate estimates of other race/ethnic groups, but include them in the estimates for all women. We use NCI's Breast Cancer Risk Assessment Tool to make the risk estimates in this article. "Lifetime risk" is the absolute risk of breast cancer up to age 90 years. Absolute risks were computed for women 30 to 84 years of age who completed the CCM ( $n = 13,919$  women from the 2000 NHIS and  $n = 13,458$  women from 2005 NHIS). We excluded 412 and 460 women from the 2000 and 2005 NHIS, respectively, because preexisting breast cancer was reported.

The data from the 2000 and 2005 NHIS were pooled for the analyses. Because the NHIS has a complex sample design that includes sample weights, all estimates are weighted by the sample weights divided by two (because two national surveys were pooled) to produce estimates for the U.S. population (14). The complex sample design of these surveys was accounted for in the estimation of SE and 95% confidence intervals (95% CI) for the pooled data. Because the estimated proportions of women with lifetime risk of  $\geq 20\%$  are small, as are certain age- and race-specific estimates of 5-year and life risk, a modified binomial CI was used when the numerators of the proportions were computed from sample sizes that were  $\leq 50$ ; otherwise a logit transformation was used to compute CI (14). Ninety-five percent confidence intervals based on the logit were computed for the transformed proportions and then were back-transformed to produce 95% CIs for the original proportions. All computations were conducted using SAS version 9.1 (15) and SAS callable SUDAAN version 9.0 (16).

## Results

Table 1 shows estimates of the total number of U.S. women, by race and age groups, with a lifetime risk of  $\geq 20\%$ . For all 80,992,209 women age 30 to 84 years in the U.S. population, 880,063 (1.09%; 95% CI, 0.95-1.24%) had a lifetime risk of  $\geq 20\%$ . The percentages of women with this risk were 1.01% for women age 30 to 39, 1.27% for women age 40 to 49, 1.58% for women age 50 to 59, 1.11% for women age 60 to 69, and 0.11% for women age 70 to 84. The percentage of non-Hispanic white women with  $\geq 20\%$  risk was 1.37% (95% CI, 1.19-1.57%), which was significantly higher than that for non-Hispanic

**Table 1.** Estimates of the total number of U.S. women with lifetime breast cancer risk of  $\geq 20\%$ , by race/ethnicity and age group, using weighted data from the years 2000 and 2005 National Health Interview Survey Cancer Control Modules

Age group, y	All women			White non-Hispanic women		
	Total no. (NHIS sample size)	No. with risk $\geq 20\%$ (NHIS sample size)	Percentage eligible for MRI (95% CI)	Total no. (NHIS sample size)	No. with risk $\geq 20\%$ (NHIS sample size)	Percentage eligible for MRI (95% CI)
30-84	80,992,209 (27,377)	880,693 (245)	1.09 (0.95-1.24)	60,163,798 (18,036)	825,011 (226)	1.37 (1.19-1.57)
30-39	20,671,173 (7,075)	209,156 (60)	1.01 (0.76-1.35)	13,931,970 (3,986)	188,449 (53)	1.35 (1.00-1.84)
40-49	21,783,294 (6,790)	276,955 (76)	1.27 (1.00-1.62)	15,763,396 (4,264)	247,324 (67)	1.57 (1.21-2.03)
50-59	16,651,303 (5,386)	262,445 (71)	1.58 (1.20-2.06)	12,731,194 (3,681)	257,101 (68)	2.02 (1.54-2.65)
60-69	10,823,873 (3,757)	119,787 (34)	1.11 (0.77-1.53)	8,587,960 (2,707)	119,787 (34)	1.39 (0.98-1.93)
70-84	11,062,566 (4,369)	12,351 (4)	0.11 (0.03-0.30)	9,149,279 (3,398)	12,351 (4)	0.14 (0.03-0.37)

(Continued on the following page)

African American women at 0.08% (95% CI, 0.03-0.21%) and that for Hispanic women at 0.15% (95% CI, 0.07-0.33%).

The prevalence of 5-year absolute risk greater than or equal to 1.67%, 2%, 3%, and 4% is presented in Table 2A. In general, prevalence is highest for white non-Hispanics, lower for African American non-Hispanic, and lowest for Hispanics. The prevalence for the various risk levels increases with age except for Hispanics, which show a reduction in prevalence between the 60-69 and the 70-84 year age groups. Forty percent or more of the white non-Hispanics and African American non-Hispanics had absolute risks that were  $\geq 1.67\%$ , which was the risk level used for inclusion in the breast cancer chemoprevention trials. The prevalence of lifetime risks greater than or equal to 6%, 8%, 10%, 12%, 14%, and 16% is presented in Table 2B. The prevalence decreases with age because an older breast cancer-free woman has a shorter risk interval to age 90 than does a younger breast cancer-free woman. Prevalence is generally highest for white non-Hispanics, lower for African American non-Hispanic, and lowest for Hispanics.

## Discussion

In April of 2007, the ACS reviewed the evidence and published guidelines for breast screening MRI based on defined levels of risk. These guidelines recommended annual breast screening with MRI as an adjunct to mammography for women with approximately 20% to 25% or greater lifetime risk of breast cancer, and women who were *BRCA* gene mutation carriers or were first-degree relatives of *BRCA* gene carriers. To assist in the evaluation of the impact that these guidelines may have on public health resources, we provide the first national estimates of the number of U.S. women who would be eligible for MRI breast screening based on ACS guidelines of  $\geq 20\%$  lifetime risk calculated with the NCI Breast Cancer Risk Assessment Tool. We calculated that 1.09%

(95% CI, 0.95-1.24%) of women age 30 to 84 years in the United States had this level of risk, which translates to 880,063 women eligible for MRI screening.

The NCI Breast Cancer Risk Assessment Tool has been validated in multiple settings, including among women at elevated risk, and has been shown to accurately predict the number of observed breast cancers over various time intervals (3, 17-21). Perhaps because this model does not incorporate second-degree relatives, including paternal relatives, or age of onset of breast cancer in relatives, the ACS guidelines do not recommend it to determine an individual woman's lifetime risk for annual MRI screening. Table 1 of the ACS guidelines (1) recommends "BRCAPRO or other models that are largely dependent on family history." Such models include BRCAPRO (22), the Claus model (23), Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA; 24), and the Tyrer-Cuzick model (25). None of these models has been tested for calibration in the general population. Amir et al. (26) provide a comprehensive review of these and other models. One small study in a high-risk clinic population with only 64 cases found that the expected numbers of cases agreed with the observed cases for the Tyrer-Cuzick model, but that predictions were somewhat too low for the NCI Breast Cancer Risk Assessment Tool, Claus model, and BRCAPRO (27). A comparison of several scenarios, including families with multiple affected relatives, indicated that the Breast Cancer Risk Assessment Tool and the Tyrer-Cuzick model usually gave the highest risks in families with at least one affected relative, and BRCAPRO gave the lowest risk (28). Euhus et al. (29) had previously shown that the Claus model and BRCAPRO usually give lower risks than the NCI Breast Cancer Risk Assessment Tool in a high-risk clinic population. Another study comparing the NCI Breast Cancer Risk Assessment Tool and the Claus model in 491 women with a family history of breast cancer found that the average lifetime risk was

**Table 1.** Estimates of the total number of U.S. women with lifetime breast cancer risk of  $\geq 20\%$ , by race/ethnicity and age group, using weighted data from the years 2000 and 2005 National Health Interview Survey Cancer Control Modules (Cont'd)

African American non-Hispanic women			Hispanic women		
Total no. (NHIS sample size)	No. with risk $\geq 20\%$ (NHIS sample size)	Percentage eligible for MRI (95% CI)	Total no. (NHIS sample size)	No. with risk $\geq 20\%$ (NHIS sample size)	Percentage eligible for MRI (95% CI)
9,430,809 (4,198)	7,738 (5)	0.08 (0.02-0.22)	8,179,990 (4,236)	12,369 (7)	0.15 (0.06-0.32)
2,722,054 (1,210)	5,207 (3)	0.19 (0.03-0.64)	2,978,974 (1,584)	944 (1)	0.03 (0.00-0.29)
2,756,900 (1,152)	1,437 (1)	0.05 (0.00-0.42)	2,320,635 (1,126)	7,175 (4)	0.31 (0.07-0.84)
1,915,417 (828)	1,095 (1)	0.06 (0.00-0.56)	1,407,714 (703)	4,250 (2)	0.30 (0.03-1.14)
1,040,974 (510)	0 (0)	0.00 (NA)	839,913 (440)	0 (0)	0.00 (NA)
995,465 (498)	0 (0)	0.00 (NA)	632,755 (383)	0 (0)	0.00 (NA)

Abbreviation: NA, not available.

higher in the Breast Cancer Risk Assessment Tool (13.2%) than in the Claus model (11.2%; ref. 30). Atypical hyperplasia was not reported in the NHIS, which could lead to underestimation of risk of breast cancer in this article. For these reasons, we believe that the Breast Cancer Risk Assessment Tool is useful to estimate an approximate number of women with a lifetime risk of  $\geq 20\%$  in the general population, although our calculation may underestimate the actual number.

A recent study by Murphy et al. (31) evaluated lifetime ( $\geq 20\%$ ) breast cancer risk among 18,190 women 40 years and older presenting for a screening mammography. Using the BRCAPRO model they found that 0.43% of this population had a combined  $\geq 20\%$  lifetime risk of breast cancer and  $>10\%$  risk of a *BRCA1* or *BRCA2* mutation. This estimate is lower than the prevalence in our Table 1 for two reasons. First, our prevalence estimates are for risk of  $\geq 20\%$  only, and not for both risk of  $\geq 20\%$  and having a mutation. Second, the Breast Cancer Risk Assessment Tool usually gives higher risk estimates than does BRCAPRO. Murphy et al. (31) also found that 1% of their screening population were predicted to be mutation carriers, although only 34% of these patients also had a lifetime risk of  $\geq 20\%$ . Their analysis cautioned that ACS guidelines may systematically exclude MRI screening for many women who have a substantial risk for *BRCA* mutation. We could not evaluate the number of U.S. women in the NHIS population with a predicted risk of *BRCA* mutation  $>10\%$  with models such as BRCAPRO because we did not have information on family structure, second-degree relatives, and ages of cancer diagnoses.

In this article we used the version of NCI's Breast Cancer Assessment Tool that was modified to produce risk estimates for African American women (13). We found that the absolute risks tended to be lower for African American women than for white women and even lower for Hispanics. This agrees with race- and

ethnicity-specific age-adjusted breast cancer incidence rates in United States in 2001-2005, which were reported to be 130.6, 117.5, and 90.1 per 100,000 population, respectively for white, African American, and Hispanic/Latino populations (32).

This study has several strengths. It is a large population-based study that is representative of U.S. women. Because of the oversampling of the African American and Hispanic populations, it has large samples sizes for these populations from which to compute distributions of risk estimates. A possible weakness of this study is that we do not have either genetic data for *BRCA* carriers or family history of cancer in second- or higher-degree relatives from which we could infer carrier status. If we had had such data and used a model that could accommodate them, we might have found higher risk estimates in some women. Although we believe that the NCI Breast Cancer Risk Assessment Tool gives well-calibrated estimates of the proportions of women with lifetime breast cancer risks of  $>20\%$ , our estimates may overestimate the proportions of women who would be declared to have such risk if assessed by BRCAPRO or other models that rely mainly on family history, as recommended in the ACS guidelines, because all such models except the Tyrer-Cuzick model tend to give lower estimates than the NCI Breast Cancer Risk Assessment Tool.

In summary, we provide the first national estimates of the number of U.S. women who would be eligible for MRI breast screening based on ACS guidelines of  $\geq 20\%$  lifetime risk along with the distributions of 5-year and lifetime risks if the NCI Breast Cancer Risk Assessment Tool is used to assess risk. We estimate that nearly 900,000 U.S. women may be eligible for MRI screening based on ACS guidelines if the NCI Breast Cancer Assessment Tool is used to assess risk. We believe that somewhat smaller numbers would be eligible if risk is assessed with BRCAPRO, the Claus model, or

**Table 2.** Prevalence of 5-year absolute risk and lifetimes absolute risk of breast cancer in U.S. women by race and age**A. Prevalence (%) of 5-year absolute risk (%) of breast cancer by race and age in U.S. women**

	≥1.67% % (95% CI)	≥2.00% % (95% CI)	≥3.00% % (95% CI)	≥4.00% % (95% CI)
All women				
30-39 y	0.0 (0.0-0.2)	0.0 (0.0-0.1)	0.0 (NA)	0.0 (NA)
40-49 y	4.1 (3.6-4.8)	1.5 (1.2-1.9)	0.3 (0.2-0.5)	0.1 (0.0-0.2)
50-59 y	13.3 (12.2-14.5)	8.5 (7.6-9.4)	1.7 (1.4-2.2)	0.8 (0.5-1.1)
60-69 y	36.4 (34.5-38.3)	18.0 (16.5-19.5)	7.1 (6.2-8.1)	2.1 (1.7-2.7)
70-84 y	44.1 (42.4-45.8)	21.8 (20.5-23.3)	10.0 (9.0-11.1)	2.5 (2.0-3.0)
White non-Hispanic				
30-39 y	0.1 (0.0-0.2)	0.0 (0.0-0.1)	0.0 (NA)	0.0 (NA)
40-49 y	5.2 (4.5-6.0)	1.9 (1.5-2.5)	0.3 (0.2-0.6)	0.1 (0.0-0.2)
50-59 y	15.5 (14.2-16.9)	10.0 (9.1-11.1)	2.2 (1.7-2.8)	1.0 (0.7-1.4)
60-69 y	39.1 (37.0-41.2)	20.6 (18.9-22.5)	8.7 (7.6-9.9)	2.6 (2.1-3.2)
70-84 y	47.3 (45.4-49.1)	25.0 (23.4-26.6)	11.8 (10.6-13.1)	2.9 (2.4-3.6)
African American non-Hispanic				
30-39 y	0.0 (NA)	0.0 (NA)	0.0 (NA)	0.0 (NA)
40-49 y	1.2 (0.6-2.1)	0.1 (0.0-0.5)	0.0 (NA)	0.0 (NA)
50-59 y	8.2 (6.1-10.8)	4.7 (2.9-7.1)	0.5 (0.1-1.6)	0.0 (NA)
60-69 y	36.4 (30.2-43.1)	6.7 (3.9-10.5)	1.2 (0.3-3.3)	0.8 (0.1-3.1)
70-84 y	42.3 (36.8-47.9)	7.4 (4.7-11.1)	1.6 (0.4-4.0)	0.6 (0.0-3.1)
Hispanic				
30-39 y	0.0 (NA)	0.0 (NA)	0.0 (NA)	0.0 (NA)
40-49 y	0.5 (0.2-1.1)	0.3 (0.0-0.8)	0.0 (NA)	0.0 (NA)
50-59 y	2.1 (1.2-3.5)	0.6 (0.2-1.5)	0.1 (0.0-0.7)	0.0 (NA)
60-69 y	10.3 (6.6-15.2)	6.8 (3.9-11.0)	1.0 (0.3-2.5)	0.6 (0.1-1.8)
70-84 y	6.9 (4.2-10.6)	3.8 (2.1-6.3)	0.1 (0.0-1.1)	0.1 (0.0-1.1)

**B. Prevalence (%) of lifetime absolute risks (%) of breast cancer by race and age in U.S. women**

	≥6.00% % (95% CI)	≥8.00% % (95% CI)	≥10.00% % (95% CI)	≥12.00% % (95% CI)	≥14.00% % (95% CI)	≥16.00% % (95% CI)
All Women						
30-39 y	93.5 (92.9-94.1)	72.4 (71.2-73.6)	47.6 (46.2-48.9)	18.3 (17.3-19.4)	5.9 (5.2-6.7)	4.5 (3.9-5.1)
40-49 y	95.5 (94.9-96.0)	69.9 (68.4-71.3)	41.8 (40.3-43.2)	20.5 (19.5-21.7)	10.4 (9.6-11.3)	7.0 (6.4-7.8)
50-59 y	81.3 (80.0-82.4)	49.6 (48.0-51.2)	22.3 (20.9-23.7)	12.6 (11.6-13.7)	8.9 (8.1-9.9)	4.6 (4.0-5.2)
60-69 y	48.9 (47.0-50.8)	18.8 (17.3-20.5)	10.8 (9.7-12.1)	6.4 (5.5-7.4)	2.8 (2.3-3.5)	2.1 (1.6-2.6)
70-84 y	10.6 (9.6-11.8)	4.3 (3.7-5.1)	1.7 (1.4-2.2)	0.8 (0.6-1.2)	0.4 (0.2-0.7)	0.3 (0.1-0.5)
White non-Hispanic						
30-39 y	100.0 (NA)	83.8 (82.5-85.1)	63.8 (62.1-65.5)	24.4 (23.0-26.0)	7.7 (6.7-8.8)	6.3 (5.5-7.3)
40-49 y	100.0 (NA)	77.6 (76.1-79.0)	51.9 (50.2-53.6)	25.4 (24.0-26.8)	12.8 (11.7-13.9)	9.3 (8.4-10.3)
50-59 y	85.2 (83.8-86.4)	54.7 (52.8-56.5)	26.5 (24.9-28.1)	15.2 (14.0-16.5)	11.2 (10.1-12.3)	5.8 (5.0-6.6)
60-69 y	53.0 (50.8-55.2)	21.8 (19.9-23.7)	13.0 (11.6-14.5)	7.7 (6.7-9.0)	3.4 (2.7-4.1)	2.4 (1.9-3.1)
70-84 y	12.2 (11.0-13.5)	5.0 (4.3-5.9)	2.0 (1.6-2.6)	1.0 (0.7-1.4)	0.5 (0.3-0.9)	0.3 (0.1-0.6)
African American non-Hispanic						
30-39 y	100.0 (NA)	63.9 (60.9-66.8)	4.9 (3.8-6.4)	2.8 (1.8-4.3)	2.8 (1.7-4.2)	0.6 (0.2-1.4)
40-49 y	100.0 (NA)	68.2 (64.7-71.5)	11.8 (9.7-14.2)	5.4 (4.0-7.2)	4.5 (3.2-6.1)	0.5 (0.1-1.3)
50-59 y	88.0 (85.3-90.2)	42.8 (39.3-46.4)	8.0 (6.0-10.6)	4.9 (3.2-7.3)	0.7 (0.1-2.0)	0.5 (0.1-1.6)
60-69 y	40.6 (35.9-45.4)	6.2 (3.8-9.6)	3.2 (1.6-5.7)	1.2 (0.3-3.3)	1.0 (0.1-3.1)	1.0 (0.1-3.1)
70-84 y	4.0 (2.0-7.0)	0.6 (0.0-3.1)	0.6 (0.0-3.1)	0.0 (NA)	0.0 (NA)	0.0 (NA)

(Continued on the following page)

**Table 2.** Prevalence of 5-year absolute risk and lifetimes absolute risk of breast cancer in U.S. women by race and age (Cont'd)**B. Prevalence (%) of lifetime absolute risks (%) of breast cancer by race and age in U.S. women**

	≥6.00% % (95% CI)	≥8.00% % (95% CI)	≥10.00% % (95% CI)	≥12.00% % (95% CI)	≥14.00% % (95% CI)	≥16.00% % (95% CI)
Hispanic						
30-39 y	55.1 (52.0-58.1)	22.0 (19.5-24.8)	3.7 (2.7-5.0)	2.5 (1.7-3.5)	1.0 (0.5-1.9)	0.2 (0.0-0.7)
40-49 y	57.4 (53.9-60.9)	19.8 (17.2-22.6)	8.3 (6.7-10.4)	4.8 (3.5-6.6)	1.4 (0.7-2.7)	0.3 (0.1-0.9)
50-59 y	35.1 (30.4-40.1)	11.7 (9.1-14.9)	5.8 (3.9-8.3)	1.6 (0.8-3.3)	0.5 (0.1-1.4)	0.5 (0.1-1.4)
60-69 y	15.4 (11.5-20.4)	7.0 (4.2-10.9)	1.6 (0.6-3.2)	1.0 (0.3-2.5)	1.0 (0.3-2.5)	0.7 (0.1-2.0)
70-84 y	1.0 (0.3-2.6)	0.1 (0.0-1.1)	0.1 (0.0-1.1)	0.1 (0.0-1.1)	0.0 (NA)	0.0 (NA)

BOADICEA. Our estimates inform the resources and public health demand for MRI and chemopreventive interventions that might be required for the U.S. population of women.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank the reviewers for their helpful comments.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 03/30/2010; revised 06/09/2010; accepted 07/16/2010; published OnlineFirst 09/14/2010.

**References**

- Saslow D, Boetes C, Burke W, et al. American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007;57:75-89.
- Breast Cancer Risk Prediction Models NCI Website. Available from: [http://riskfactor.cancer.gov/cancer\\_risk\\_prediction/breast.html](http://riskfactor.cancer.gov/cancer_risk_prediction/breast.html).
- Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. *J Natl Cancer Inst* 1999;91:1541-8.
- Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of breast cancer risk prediction models in clinical practice. *J Clin Oncol* 2003;21:593-601.
- Zakhireh J, Gomez R, Esserman L. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer. *Eur J Cancer* 2008;44:2742-52.
- Elsamaly H, Elzawawi MS, Mohammed S, Herial N. Increasing accuracy of detection of breast cancer with 3-T MRI. *Am J Roentgenol* 2009;192:1142-8.
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst* 1998;90:1371-88.
- Pleis JR, Schiller JS, Benson V, National Center for Health Statistics. Summary health statistics U.S. adults: National Health Interview Survey, 2000. *Vital Health Stat* 10 (215) 2003;10.
- Pleis JR, Lethbridge-Ceiku M, National Center for Health Statistics. Summary health statistics U.S. adults: National Health Interview Survey, 2005. *Vital Health Stat* 10 (232) 2006;10.
- Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989;81:1879-86.
- National Health Interview Survey (NHIS). Available from: <http://www.cdc.gov/nchs/nhis.htm>.
- Anderson SJ, Ahn S, Duff K. NSABP breast cancer prevention trial risk assessment program, Version 2. NSABP Biostatistical Center technical report. Pittsburgh (PA): Department of Biostatistics, University of Pittsburgh; 1992.
- Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. *J Natl Cancer Inst* 2007;99:1782-92.
- Korn EL, Graubard BI. Analysis of health surveys. New York (NY): John Wiley & Sons; 1999, pp. 22-8, 64-8.
- SAS Institute Inc. SAS/STAT 9.1 user's guide, version 9.1. Cary (NC): SAS Institute Inc; 2004.
- Research Triangle Institute. SUDAAN language manual, release 9.0. Research Triangle Park (NC): Research Triangle Institute; 2004.
- Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. *J Natl Cancer Inst* 2001;93:358-66.
- Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. *J Natl Cancer Inst* 1994;86:620-5.
- Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. *J Natl Cancer Inst* 1994;86:600-7.
- Bondy ML, Newman LA. Assessing breast cancer risk: evolution of the Gail model. *Natl Cancer Inst* 2006;98:1172-3.
- Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European prospective investigation into cancer and nutrition cohort. *J Natl Cancer Inst* 2006;98:1686-93.
- Parmigiani G, Chen S, Iversen ES, Jr., et al. Validity of models for predicting BRCA1 and BRCA2 mutations. *Ann Intern Med* 2007;147:441-50.
- Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. *Breast Cancer Res Treat* 1993;28:115-20.
- Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *Br J Cancer* 2008;98:1457-66.

25. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. *Stat Med* 2004;23:1111–30.
26. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. *J Natl Cancer Inst* 2010;102:680–91.
27. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. *J Med Genet* 2003;40:807–14.
28. Gail MH, Mai PL. Comparing breast cancer risk assessment models. *J Natl Cancer Inst* 2010;102:665–8.
29. Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. *Breast J* 2002;8:23–7.
30. McTiernan A, Kuniyuki A, Yasui Y, et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2001;10:333–8.
31. Murphy CD, Lee JM, Drohan B, et al. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing. *Cancer* 2008;113:3116–20.
32. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–49.

# Cancer Epidemiology, Biomarkers & Prevention

**AACR** American Association  
for Cancer Research

## Five-Year and Lifetime Risk of Breast Cancer among U.S. Subpopulations: Implications for Magnetic Resonance Imaging Screening

Barry I. Graubard, Andrew N. Freedman and Mitchell H. Gail

*Cancer Epidemiol Biomarkers Prev* 2010;19:2430-2436. Published OnlineFirst September 14, 2010.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1055-9965.EPI-10-0324](https://doi.org/10.1158/1055-9965.EPI-10-0324)

**Cited articles** This article cites 24 articles, 3 of which you can access for free at:  
<http://cebp.aacrjournals.org/content/19/10/2430.full#ref-list-1>

**Citing articles** This article has been cited by 3 HighWire-hosted articles. Access the articles at:  
<http://cebp.aacrjournals.org/content/19/10/2430.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cebp.aacrjournals.org/content/19/10/2430>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.